We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

The Effects of Strawberries on Blood Cholesterol.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03441620
Recruitment Status : Completed
First Posted : February 22, 2018
Last Update Posted : March 16, 2021
University of Oklahoma
Oklahoma State University
Information provided by (Responsible Party):
Arpita Basu, University of Nevada, Las Vegas

Brief Summary:
In this study, we propose to investigate the effects of dietary achievable doses of strawberries on serum LDL-cholesterol (LDL-C) and related lipid profiles, measures of glycemia and insulin resistance, and biomarkers of inflammation in a 14 week controlled crossover study.

Condition or disease Intervention/treatment Phase
Hyper-LDL-cholesterolemia Metabolic Syndrome Dietary Supplement: strawberries Other: Control powder Not Applicable

Detailed Description:

The screen visit will involve an 8 hour fasting state and the following procedures:

  • Completing screening questionnaire
  • Measuring height, weight, blood pressure, and waist size
  • Drawing about 30mL blood for blood glucose and lipids and comprehensive metabolic panel All subjects will be asked to follow usual diet and lifestyle, and refrain from other sources of berries and related products while on the study. Subjects will also maintain 3-day food records at screen, 4, 9, and 14 weeks of the study. Height, weight, blood pressure and waist circumference will be measured by trained personnel at MPE 326 (KNS facility for clinical research). Blood draws will be performed by trained phlebotomists (to be hired) at MPE 326, and all procedures will be performed by trained research personnel [PI &Co-PI: Basu, Izuora and graduate student]. In case of blood pressure, an average of at least three readings, 10 min apart, will be measured at each visit for each participant. Blood glucose (fasting and postprandial at two hours) will be determined at each time point. The oral glucose tolerance tests will be conducted at MPE 326 and blood samples will be sent to Quest Diagnostics, Las Vegas. Insulin resistance will be calculated using the homoeostatic model assessment (HOMA-IR). The HOMA-IR is a standard and widely used formula in calculating insulin resistance based on fasting glucose values. Screening and follow-up tests will include clinical laboratory tests for blood glucose, lipids, NMR profiles, C-reactive protein and metabolic panel to determine effects of the intervention.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 33 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Effects of Strawberries on LDL Cholesterol and Insulin Resistance in Overweight/Obese Adults With the Metabolic Syndrome.
Actual Study Start Date : February 1, 2018
Actual Primary Completion Date : January 31, 2021
Actual Study Completion Date : January 31, 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Placebo Comparator: Control
Calorie and fiber-matched control powder
Other: Control powder
Control powder matched for fiber and strawberries

Experimental: Strawberry one serving
Freeze-dried powder equivalent to one serving fresh strawberries per day.
Dietary Supplement: strawberries
Freeze-dried strawberry powder

Experimental: Strawberry two-half servings
Freeze-dried powder equivalent to 2.5 serving fresh strawberries per day.
Dietary Supplement: strawberries
Freeze-dried strawberry powder

Primary Outcome Measures :
  1. Serum Lipid profiles [ Time Frame: 14 weeks ]
    Serum LDL, total and HDL cholesterol, triglycerides

  2. Glycemic control [ Time Frame: 14 weeks ]
    Blood glucose

  3. Serum lipid particle concentrations [ Time Frame: 14 weeks ]
    Molar concentrations of serum lipids and particle size

  4. Diabetes control [ Time Frame: 14 weeks ]
    Insulin resistance

Secondary Outcome Measures :
  1. Systemic Inflammation [ Time Frame: 14 weeks ]
    Serum C-reactive protein and adipokines

  2. Systemic Anthocyanins [ Time Frame: 14 weeks ]
    Strawberry anthocyanin metabolites measured in serum

  3. Serum metabolomics [ Time Frame: 14 weeks ]
    primary and lipid metabolites in serum

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • elevated total and LDL cholesterol (>116 mg/dL)
  • body mass index (> or = 30 kg/m2)
  • features of the metabolic syndrome

Exclusion Criteria:

  • taking glucose and lipid lowering medications (e.g. statins, metformin)
  • history of chronic conditions (diabetes, CHD, anemia, renal diseases)
  • allergic to strawberries
  • pregnant and/or lactating
  • smoking
  • vegetarian or consuming special diet

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03441620

Layout table for location information
United States, Nevada
University of Nevada at Las Vegas
Las Vegas, Nevada, United States, 89154
United States, Oklahoma
University of Oklahoma Health Sciences Center, OCTSI
Oklahoma City, Oklahoma, United States, 73104
Oklahoma State University
Stillwater, Oklahoma, United States, 74078
Sponsors and Collaborators
University of Nevada, Las Vegas
University of Oklahoma
Oklahoma State University
Layout table for investigator information
Principal Investigator: Arpita Basu, PHD University of Nevada at Las Vegas
Layout table for additonal information
Responsible Party: Arpita Basu, Associate Professor, University of Nevada, Las Vegas
ClinicalTrials.gov Identifier: NCT03441620    
Other Study ID Numbers: 1119274
First Posted: February 22, 2018    Key Record Dates
Last Update Posted: March 16, 2021
Last Verified: March 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Metabolic Syndrome
Pathologic Processes
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases